Advertisement

Reactions Weekly

, Volume 1714, Issue 1, pp 131–131 | Cite as

Crizotinib/osimertinib

Development of resistance to osimertinib in lung adenocarcinoma, rash and diarrhoea: case report
Case report
  • 7 Downloads

Reference

  1. Zeng L, et al. GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma. Journal of Thoracic Oncology 13: e114-e116, No. 7, Jul 2018. Available from: URL: http://doi.org/10.1016/j.jtho.2018.02.005 - China

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations